Gastrointestinal motility in patients with neuroendocrine tumors Abstract #118

Introduction: Diarrhea is the most common symptom in patients with intestinal neuroendocrine tumors (NET). Somatostatin analogues reduce stool frequency and may increase gastrointestinal transit time (GITT). Motility tracking system® MTS-1 (MTS) (Motilis, Switzerland) is a novel, safe, almost non-invasive and easy-to-perform method for description of gastrointestinal motility.
Aim(s): To compare gastrointestinal transit times and motility patterns in patients with carcinoid syndrome before and after treatment with Sandostatin® LAR with those of healthy individuals.
Materials and methods: For MTS, a small magnetic pill (6x15 mm) was ingested and a matrix of magnetic field sensors (4x4) tracked the position of the magnet defined by five coordinates (position: x, y, z, angle: θ, φ). Ten patients with carcinoid syndrome (six men, age 32-73 years, median 66) and positive octreotide scintigraphy were investigated for 6-7 hours after three hours fast. Results were compared to 10 healthy subjects. Patients were studied before and during treatment with Sandostatin® LAR (30 mg injections given twice with an interval of three weeks).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Tine Gregersen

To read results and conclusion, please login ...

Further abstracts you may be interested in

#141 Incidence of second primary tumors in patients with neuroendocrine tumors
Introduction: Based on epidemiological data from SEER 1950-1999, 22.4% cases of non-carcinoid second primary tumors have been described in patients diagnosed with neuroendocrine tumors. The incidence of this type of tumors varies, depending on the series assessed.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD Juan Manuel OConnor
Authors: Pesce V, OConnor J, Mendez G, Bestani C, ...
#349 Gastrointestinal Stromal Tumor (GIST) Of The Esophagus In A Patient With MEN-1 And-Related Pancreatic Gastrinoma
Introduction: Both Multiple Endocrine Neoplasia type 1 (MEN-1; OMIM #613733)-related-gastrinomas and Gastrointestinal Stromal Tumors (GISTs; OMIM #606764) are rare neoplasms and their association has been rarely reported so far.
Conference:
Category: Basic
Presenting Author: Dr Roberta E Rossi
#1429 Evaluate the Accuracy of Pathological Diagnosis on Biopsy Specimens from Gastrointestinal Neuroendocrine Tumors
Introduction: Gastrointestinal neuroendocrine neoplasms (GI-NENs) is a highly heterogeneous tumor. The accuracy of pathological diagnosis on the biopsy is crucial for GI-NENs but rarely investigated
Conference: 13th Annual ENETS conference (2016)
Category: Pathology, grading, staging
Presenting Author: Doctor Li Sun
Authors: Sun L, Li S, Li J, Lu M, ...
#1841 The Characteristics and Survivals of Gastrointestinal Neuroendocrine Tumors, A Single Center Experience from Developing Country
Introduction: Gastrointestinal neuroendocrine tumors (GINETs) are a heterogeneous group of tumors with variable behaviors. We analyzed baseline characteristics and outcomes of GINETs and impact of the tumor grade on the overall survival.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment – Chemotherapy, medical treatment - others
Presenting Author: Doctor Jamshed Ali
Authors: Ali J, Qubtia M, Hassan A U, Ahmad U, ...
#1851 Ecological Study to Assess the Management of Gastroenteropancreatic Neuroendocrine Tumors in Spain
Introduction: Neuroendocrine tumors (NET) have widely varying characteristics, localizations, and treatments. Consequently, a multidisciplinary approach to diagnosis and treatment is necessary. Given the heterogeneous management of this disease, we conducted an ecological survey to assess usual clinical practice in Spain.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Raquel Guardeño